CareDx, Inc. announced the results of its cohort studies of blood samples from the multicenter CARGO and CARGO II heart transplant observational studies, and from the KARGO kidney transplant study during a presentation today at The World Transplant Congress in San Francisco, CA.
In his oral abstract, Dr. Robert Woodward, Ph.D. and co-authors from CareDx demonstrated that graft-derived cfDNA proportion in heart transplant and kidney transplant recipient's blood is significantly higher in patients who had a biopsy-confirmed rejection compared to that found in transplant recipients who did not have any evidence of rejection at the time of blood sampling. There was a 10-fold median cfDNA proportion increase in the CARGO and 5-fold in the CARGO II heart recipients with biopsy-proven rejection in comparison to the cfDNA levels from patients without rejection. In kidney transplant recipients, the median graft-derived cfDNA was 3-fold higher in the KARGO patients with biopsy-proven rejection in comparison to the cfDNA levels in blood from kidney recipients without rejection.
"These results represent just the tip of the iceberg of data we expect to emanate from existing CareDx repositories of blood samples and clinical data that will accelerate our understanding and development of graft-derived, cell-free DNA test solutions for managing the care of kidney as well as with AlloMap(R) for heart transplant recipients,"
said James Yee, MD, Chief Medical Officer. "CareDx is also starting new, prospective studies applying this promising new molecular biomarker to transplant recipients."
The World Transplant Congress is the second joint meeting of the American Society of Transplant Surgeons (ASTS), The Transplantation Society (TTS) and the American Society of Transplantation (AST). The event brings together the largest group of transplant scientists, physicians, surgeons, trainees, nurses, organ procurement personnel, pharmacists and other associated transplant professionals from around the world.